Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
ASSETS
Cash and cash equivalents	$ 20,745	$ 14,032
Marketable securities	0	11,125
Prepaid and other current assets	461	815
Total current assets	21,206	25,972
Property and equipment, net	87	100
Other assets	847	1,081
Total assets	22,140	27,153
Liabilities
Accounts payable	64	1,490
Accrued liabilities	4,556	4,486
Total current liabilities	4,620	5,976
Other long-term liabilities	536	624
Total liabilities	5,156	6,600
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at March 31, 2020 and December 31, 2019, respectively	0	0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 10,638,771 and 10,528,689 shares at March 31, 2020 and December 31, 2019, respectively	11	11
Additional paid-in capital	439,330	438,911
Treasury stock, at cost; 11,080 shares at March 31, 2020 and December 31, 2019	(708)	(708)
Accumulated deficit	(421,390)	(417,400)
Accumulated other comprehensive income	0	2
Total Caladrius Biosciences, Inc. stockholders' equity	17,243	20,816
Noncontrolling interests	(259)	(263)
Total stockholders' equity	16,984	20,553
Liabilities and Equity, Total	$ 22,140	$ 27,153